NervGen Pharma
NASDAQ: NGENFounded 2017 · British Columbia, Canada corporation · 2 known investors
Find your way into NervGen Pharma
288 people in our graph share verified history with the NervGen Pharma team — schools, employers, funds. One of them is your warm intro.
Seth Lieblichunlockedknows Daniel Mikol · together at Amgen (overlapped)
×8knows the team · via Amgen
×3knows the team · via AbbVie
NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Founders & leadership
NervGen Pharma was founded in 2017 by Harold Punnett and Jerry Silver.
HP
Harold PunnettinCo-founder
JS
Jerry SilverCo-founder
WA
William AdamsExecutive
PB
Paul BrennaninPresident and Chief Executive Officer2019–2022
DM
Daniel MikolinChief Medical Officer2021–2025Daniel Mikol is an executive at NervGen Pharma, a clinical-stage biotech company developing therapies for neurological conditions including spinal cord injury. He has experience in clinical drug development across all phases with a focus on neuroscience.
AR
Adam RogersinChief Executive Officer
RK
Randall KayeNamed on SEC filing
BB
Brian BayleyNamed on SEC filing
MA
Michael AbramsNamed on SEC filing
BR
Bill RadvakNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 7 rounds · 2018–2021
▶$651.8KraisedDec 2021 · 17 investors · OtherRule 506(b)
▶$651.8KraisedDec 2021 · 17 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Harold PunnettDirector
- Michael AbramsDirector
- Brian BayleyDirector
- Bill RadvakDirector
- Paul BrennanDirector, Executive Officer
- Randall KayeDirector
- Daniel MikolExecutive Officer
- Glenn IvesDirector
- Krista McKerracherDirector
- William AdamsExecutive Officer
- Offering amount
- $1.1M
- Amount sold
- $651.8K
- First sale
- Nov 2021
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$2.2MraisedAug 2021 · 23 investors · OtherRule 506(b)
▶$2.2MraisedAug 2021 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Randall KayeDirector
- Brian BayleyDirector
- Daniel MikolExecutive Officer
- Bill RadvakDirector
- Michael AbramsDirector
- Paul BrennanDirector, Executive Officer
- William AdamsExecutive Officer
- Harold PunnettDirector
- Offering amount
- $5.4M
- Amount sold
- $2.2M
- Sales commissions
- $153.6K
- Placement agents
- Arcadia Securities, LLC, Haywood Securities (USA) Inc.
- First sale
- Aug 2020
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$263.7KraisedAug 2021 · 3 investors · OtherRule 506(b)
▶$263.7KraisedAug 2021 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Brian BayleyDirector
- William AdamsExecutive Officer
- Michael AbramsDirector
- Randall KayeDirector
- Bill RadvakDirector
- Daniel MikolExecutive Officer
- Paul BrennanDirector, Executive Officer
- Harold PunnettDirector
- Offering amount
- $442.3K
- Amount sold
- $263.7K
- First sale
- Aug 2021
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$285.1KraisedJun 2021 · 13 investors · OtherRule 506(b)
▶$285.1KraisedJun 2021 · 13 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Randall KayeDirector
- William AdamsExecutive Officer
- Brian BayleyDirector
- Harold PunnettDirector
- Michael AbramsDirector
- Paul BrennanDirector, Executive Officer
- Bill RadvakDirector
- Daniel MikolExecutive Officer
- Offering amount
- $650.1K
- Amount sold
- $285.1K
- First sale
- May 2020
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$1.5MraisedNov 2019 · 1 investors · OtherRule 506(b)
▶$1.5MraisedNov 2019 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Ernest WongExecutive Officer, Director
- Robert PilzExecutive Officer
- Amy FrankeExecutive Officer
- Harold PunnettDirector
- Bill RadvakExecutive Officer, Director
- Michael AbramsDirector
- Brian BayleyDirector
- Denis BoscExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Nov 2019
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$1.2MraisedMar 2019 · 28 investors · OtherRule 506(b)
▶$1.2MraisedMar 2019 · 28 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Harold PunnettDirector
- William Joseph RadvakExecutive Officer, Director
- Brian BayleyDirector
- Robert PilzExecutive Officer
- Ernest WongExecutive Officer, Director
- Michael Jeffrey AbramsDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- Sales commissions
- $83.8K
- Placement agents
- Haywood Securities (USA) Inc.
- First sale
- Mar 2019
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
▶$111.4KraisedSep 2018 · 5 investors · OtherRule 506(b)
▶$111.4KraisedSep 2018 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- HAROLD MARTIN PUNNETTDirector
- WILLIAM JOSEPH RADVAKExecutive Officer, Director, Promoter
- ROBERT GERHARD PILZExecutive Officer
- ERNEST SHINGYAN WONGExecutive Officer, Director
- MICHAEL JEFFREY ABRAMSDirector
- BRIAN ERIC BAYLEYDirector
- Offering amount
- $111.4K
- Amount sold
- $111.4K
- First sale
- Sep 2018
- Incorporated
- Corporation, British Columbia, Canada, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Biogen Idec92 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Seeking Alpha66 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
PepGen65 shared keywordsPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Urogen50 shared keywordsUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
Robinhood49 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Amgen Europe43 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
Companies competing with NervGen Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does NervGen Pharma do?
- NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
- Who founded NervGen Pharma?
- NervGen Pharma was founded by Harold Punnett, Jerry Silver in 2017.
- Who are NervGen Pharma's investors?
- NervGen Pharma's investors include CWRU Technology Ventures, SCI Ventures.
- How much funding has NervGen Pharma raised?
- NervGen Pharma has disclosed $6.2M raised across 7 rounds.